-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,382 in Common Shares

PUBT·11/12/2026 13:01:43
Listen to the news
AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,382 in Common Shares
  • AIM ImmunoTech CEO, President and director Thomas K Equels purchased 39,000 common shares at $0.138 per share.
  • His direct beneficial ownership increased to 293,095 common shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051199), on November 12, 2026, and is solely responsible for the information contained therein.